Prelude Therapeutics Files 2025 Proxy Statement
Ticker: PRLD · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1678660
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Prelude Therapeutics filed its proxy statement for the June 12 meeting. Vote your shares!
AI Summary
Prelude Therapeutics Inc. filed its definitive proxy statement on April 29, 2025, for its annual meeting on June 12, 2025. The company, incorporated in Delaware with its principal office in Wilmington, DE, is seeking shareholder approval for matters related to its governance and operations. The filing indicates no fee was required for this submission.
Why It Matters
This filing provides shareholders with crucial information regarding the company's upcoming annual meeting, including proposals that will be voted on, which can impact corporate governance and strategic direction.
Risk Assessment
Risk Level: low — This is a routine proxy filing for an annual meeting and does not contain new financial or strategic information that would inherently increase risk.
Key Numbers
- 20250429 — Filing Date (The date Prelude Therapeutics filed this proxy statement.)
- 20250612 — Meeting Date (The date of Prelude Therapeutics' annual shareholder meeting.)
Key Players & Entities
- Prelude Therapeutics Inc. (company) — Registrant
- April 29, 2025 (date) — Filing Date
- June 12, 2025 (date) — Annual Meeting Date
- Wilmington, DE (location) — Company Headquarters
FAQ
What is the purpose of this DEF 14A filing?
This filing is a definitive proxy statement filed by Prelude Therapeutics Inc. to provide shareholders with information for the annual meeting scheduled for June 12, 2025.
When was this proxy statement filed?
The definitive proxy statement was filed on April 29, 2025.
What is the fiscal year end for Prelude Therapeutics Inc.?
The fiscal year end for Prelude Therapeutics Inc. is December 31.
Where is Prelude Therapeutics Inc. located?
Prelude Therapeutics Inc. is located at 175 Innovation Boulevard, Wilmington, DE 19805.
Was there a fee required for this filing?
No fee was required for this filing, as indicated by the checkbox next to 'No fee required'.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Prelude Therapeutics Inc (PRLD).